Edition:
United Kingdom

Intercept Pharmaceuticals Inc (ICPT.OQ)

ICPT.OQ on NASDAQ Stock Exchange Global Select Market

68.73USD
20 Apr 2018
Change (% chg)

$-0.50 (-0.72%)
Prev Close
$69.23
Open
$69.30
Day's High
$70.56
Day's Low
$68.61
Volume
292,290
Avg. Vol
288,617
52-wk High
$135.59
52-wk Low
$51.11

Select another date:

Thu, Apr 5 2018

BRIEF-Intercept Pharmaceuticals Announces Pricing Of Upsized $250 Mln Public Offering And Concurrent Private Placement Of Common Stock

* INTERCEPT PHARMACEUTICALS ANNOUNCES PRICING OF UPSIZED $250 MILLION PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT OF COMMON STOCK

BRIEF-Intercept Sees Ocaliva Net Sales To Fall In Quarter Ended March 31

* EXPECTS NET SALES OF OCALIVA FOR QUARTER ENDED MARCH 31, TO BE SLIGHTLY LOWER THAN NET SALES OF OCALIVA FOR QUARTER ENDED DEC 31, 2017​ Source text (https://bit.ly/2uINGwG) Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Intercept Pharma Says U.S. Court Granted Defendants Motion & Dismissed With Prejudice Derivative Lawsuit Purportedly Brought On Behalf Of Company

* INTERCEPT PHARMA - U.S. COURT GRANTED DEFENDANTS MOTION & DISMISSED WITH PREJUDICE DERIVATIVE LAWSUIT PURPORTEDLY BROUGHT ON BEHALF OF COMPANY

BRIEF-Intercept Pharma Says Sumitomo Dainippon Pharma Enters Into Amendment To Certain License Agreement

* INTERCEPT PHARMA SAYS ON FEB 13, CO, SUMITOMO DAINIPPON PHARMA ENTERED INTO AMENDMENT TO CERTAIN LICENSE AGREEMENT DATED AS OF MARCH 29, 2011

BRIEF-Intercept Pharmaceuticals Reports Q4 Net Loss Per Common & Potential Common Share $4.43

* INTERCEPT PHARMACEUTICALS REPORTS FULL YEAR AND FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Intercept Announces Updated U.S. Prescribing Information For Ocaliva

* INTERCEPT ANNOUNCES UPDATED U.S. PRESCRIBING INFORMATION FOR OCALIVA® (OBETICHOLIC ACID) TO REINFORCE APPROPRIATE DOSING IN PBC PATIENTS WITH ADVANCED CIRRHOSIS

BRIEF-Intercept Pharma Says Shifting Guidance For Announcement Of Phase 3 Reverse Trial In Nash Patients With Compensated Cirrhosis To Q1 2018

* INTERCEPT PHARMA SAYS SHIFTING GUIDANCE FOR ANNOUNCEMENT OF PHASE 3 REVERSE TRIAL IN NASH PATIENTS WITH COMPENSATED CIRRHOSIS TO Q1 2018 - SEC FILING Source text: (http://bit.ly/2CgH2Og) Further company coverage:

BRIEF-Intercept Pharma reports qtrly ‍revenue $41.3 mln vs $5.2 million​

* Intercept Pharmaceuticals reports third quarter 2017 financial results and provides business update

BRIEF-Intercept Pharma posts positive results from Phase 2 AESOP trial

* Intercept announces positive results from Phase 2 AESOP trial evaluating OCA for the treatment of patients with primary sclerosing cholangitis at The Liver Meeting 2017

Select another date: